Ellicott City, MD, United States of America

Samuel Ray Denmeade

This inventor holds 25 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Cancer Treatment. Top assignees: Johns Hopkins University, Genspera, Inc., University of Victoria. Active years: 2001-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Samuel Ray Denmeade. Retrieved from https://idiyas.com/inventor/samuel-ray-denmeade

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 9)

% Patents Active = 56.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 3)

Average Co-Inventor Count = 2.8

ph-index = 9

Forward Citations = 250(Granted Patents)

Location History:

Baltimore, MD (US) (2001 - 2003)
Ellicot City, MD (US) (2007 - 2015)
Ellicott City, MD (US) (2003 - 2023)

Company Filing History:

14 out of 3,803

Johns Hopkins University

University of Victoria

University of Victoria Innovatiion and Development Corporation

patent

7. 2 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 2001-2026

Loading Chart...

Areas of Expertise:

Prodrugs

Cancer Therapy

Nanoparticles

PSMA

Tumor Activation

Albumin

Emetine Derivatives

Peptide Activation

Tissue Specific

Protease Activation

Detection Methods

Activation Sequences

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12691158 - ALBUMIN-PROAEROLYSIN PRODRUGS (2026-07-28),

2. 11780833 - Emetine derivatives, prodrugs containing same, and methods of treating conditions using same (2023-10-10),

3. 10967046 - Albumin-proaerolysin prodrugs (2021-04-06),

4. 10596226 - Albumin-proaerolysin prodrugs (2020-03-24),

5. 10369113 - Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer (2019-08-06),

6. 9492560 - Emetine derivatives, prodrugs containing same, and methods of treating conditions using same (2016-11-15),

7. 9422234 - Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer (2016-08-23),

8. 8957016 - Tumor activated prodrugs (2015-02-17),

9. 8822406 - Tumor activated prodrugs (2014-09-02),

10. 8772226 - Methods and compositions for the detection of cancer (2014-07-08),

11. 8669231 - Activation of peptide prodrugs by hK2 (2014-03-11),

12. 8450280 - Activation of peptide prodrugs by hK2 (2013-05-28),

13. 8258256 - Compositions and methods for the treatment of cancer (2012-09-04),

14. 7906477 - Activation of peptide prodrugs by hK2 (2011-03-15),

15. 7838266 - Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer (2010-11-23),

Samuel Ray Denmeade: Pioneering Innovations in Cancer Treatment

Introduction

Samuel Ray Denmeade is a distinguished inventor based in Ellicott City, MD, known for his groundbreaking contributions in the field of cancer treatment. With a prolific portfolio of 24 patents, Denmeade has focused on developing innovative therapeutics aimed at improving patient outcomes in oncology.

Latest Patents

Denmeade's latest patents include a range of compounds described as emetine derivatives, which can act as prodrugs that selectively release emetine in specific cellular conditions. These compounds incorporate a blocking group onto the emetine molecule, allowing it to activate through hydrolysis in cancer or tumor microenvironments. This innovative approach reduces cytotoxicity compared to standard emetine, making it less harmful to non-cancerous cells. His work encompasses treatments for various cancers, including breast, prostate, lung cancer, and leukemia.

Additionally, Denmeade has developed a series of albumin-proaerolysin prodrugs aimed at treating cancer more effectively. His prodrug compositions include those activated by prostate-specific antigen (PSA), integrating advanced methodologies to improve targeting and efficacy in cancer therapies.

Career Highlights

Denmeade's career includes significant positions at notable institutions such as The Johns Hopkins University and Genspera, Inc. His work has not only contributed to academic advancements but also brought innovative cancer treatments closer to clinical application.

Collaborations

Throughout his career, Denmeade has collaborated with esteemed colleagues, including John Tod Isaacs and Hans Lilja. These partnerships have further enriched his research and expanded the impact of his inventions in the field of oncology.

Conclusion

Samuel Ray Denmeade exemplifies the spirit of innovation in cancer research and treatment. His extensive portfolio of patents reflects a commitment to discovering novel therapies that could significantly improve cancer patient outcomes. With ongoing collaborations and advancements in his work, Denmeade continues to pave the way for future innovations in the medical field.

Profile summary based on public USPTO records.